Related Experiment Videos
Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
Y Z Patt1, M M Hassan, R D Lozano
1Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
American Journal of Clinical Oncology
|June 17, 2000
Abstract:
Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.